Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma

99mTc-methoxyisobutyl isonitrile (MIBI) is a suitable transport substrate for the multidrug resistance gene product P-glycoprotein (P-gp) and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could...

Full description

Bibliographic Details
Main Authors:	Chai, Xiangting, Liu, Qiaoyu, Shao, Wenyu, Zhang, Feng, Wang, Xuehao, Wang, Hai
Format:	Online
Language:	English
Published:	Editorial Department of Journal of Biomedical Research 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596066/

id	pubmed-3596066
recordtype	oai_dc
spelling	pubmed-35960662013-04-02 Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma Chai, Xiangting Liu, Qiaoyu Shao, Wenyu Zhang, Feng Wang, Xuehao Wang, Hai Research Paper 99mTc-methoxyisobutyl isonitrile (MIBI) is a suitable transport substrate for the multidrug resistance gene product P-glycoprotein (P-gp) and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could promote the accumulation of MIBI by inhibiting P-gp activities, a feature that can be taken advantage of for enhancing 99mTc-MIBI imaging. In the current study, we sought to investigate whether bromocriptine enhanced the uptake of 99mTc-MIBI in hepatocellular carcinoma patients. Sixty primary hepatocellular carcinoma patients received 99mTc-MIBI single photon emission computer tomgraphy (SPECT) prior to surgery. 99mTc-MIBI SPECT was performed 15 and 120 min after injection of 20 mCi 99mTc-MIBI, and early uptake, delayed uptake (L/Nd), and washout rate (L/Nwr) of 99mTc-MIBI were obtained. In addition, a second 99mTc-MIBI SPECT was performed according to the same method 48 h after bromocriptine administration. We found that, prior to bromocriptine administration, significant MIBI uptake in tumor lesions was noted in only 10 (16.7%, 10/60) patients with hepatocellular carcinoma. No significant MIBI uptake was observed in the tumor lesions of the remaining 50 (83.3%, 50/60) hepatocellular carcinoma patients. Following bromocriptine administration, all the patients without apparent MIBI uptake demonstrated significant MIBI uptake on 99mTc-MIBI SPECT (P < 0.05). Our findings indicate that bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma. Editorial Department of Journal of Biomedical Research 2012-05 2012-04-12 /pmc/articles/PMC3596066/ /pubmed/23554746 http://dx.doi.org/10.7555/JBR.26.20110075 Text en © 2012 by the Journal of Biomedical Research. All rights reserved. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Chai, Xiangting Liu, Qiaoyu Shao, Wenyu Zhang, Feng Wang, Xuehao Wang, Hai
spellingShingle	Chai, Xiangting Liu, Qiaoyu Shao, Wenyu Zhang, Feng Wang, Xuehao Wang, Hai Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
author_facet	Chai, Xiangting Liu, Qiaoyu Shao, Wenyu Zhang, Feng Wang, Xuehao Wang, Hai
author_sort	Chai, Xiangting
title	Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
title_short	Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
title_full	Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
title_fullStr	Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
title_full_unstemmed	Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma
title_sort	bromocriptine enhances the uptake of 99mtc-mibi in patients with hepatocellular carcinoma
description	99mTc-methoxyisobutyl isonitrile (MIBI) is a suitable transport substrate for the multidrug resistance gene product P-glycoprotein (P-gp) and widely used for tumor imaging. Bromocriptine has been shown to inhibit the ATPase activity and the function of P-gp. We hypothesized that bromocriptine could promote the accumulation of MIBI by inhibiting P-gp activities, a feature that can be taken advantage of for enhancing 99mTc-MIBI imaging. In the current study, we sought to investigate whether bromocriptine enhanced the uptake of 99mTc-MIBI in hepatocellular carcinoma patients. Sixty primary hepatocellular carcinoma patients received 99mTc-MIBI single photon emission computer tomgraphy (SPECT) prior to surgery. 99mTc-MIBI SPECT was performed 15 and 120 min after injection of 20 mCi 99mTc-MIBI, and early uptake, delayed uptake (L/Nd), and washout rate (L/Nwr) of 99mTc-MIBI were obtained. In addition, a second 99mTc-MIBI SPECT was performed according to the same method 48 h after bromocriptine administration. We found that, prior to bromocriptine administration, significant MIBI uptake in tumor lesions was noted in only 10 (16.7%, 10/60) patients with hepatocellular carcinoma. No significant MIBI uptake was observed in the tumor lesions of the remaining 50 (83.3%, 50/60) hepatocellular carcinoma patients. Following bromocriptine administration, all the patients without apparent MIBI uptake demonstrated significant MIBI uptake on 99mTc-MIBI SPECT (P < 0.05). Our findings indicate that bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma.
publisher	Editorial Department of Journal of Biomedical Research
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596066/
_version_	1611961655113023488

Bromocriptine enhances the uptake of 99mTc-MIBI in patients with hepatocellular carcinoma

Similar Items